Press & Media

SkinMedica Launches New Rejuvenize Peel�

Treats moderate to severe skin conditions

Carlsbad, Calif. - October 15, 2009 - SkinMedica, Inc. launches new Rejuvenize Peel™, formulated to treat moderate to severe skin conditions such as acne, scarring, melasma and sun damage.

Rejuvenize Peel™ is a blend of Salicylic Acid, Lactic Acid, Resorcinol, Panthenol and Isoceteth-20 with the addition of .3% Retinoic Acid. Deeper than SkinMedica Vitalize Peel®, Rejuvenize Peel™ produces a moderate amount of peeling for 2-5 days, and can be repeated every 4-6 weeks.

CLINICAL STUDY:
A recent clinical study of female subjects, aged 23-62 years, with mild to moderate facial photoaging, melasma, hyperpigmentation, or mild acne receiving three consecutive peels (once every four weeks) discovered the following results:

80% felt it improved evenness of skin tone and appearance of age spots and pigmentation
85% felt it made skin look healthier and more youthful
90% felt it improved smoothness of skin
90% felt it improved overall condition of skin

SkinMedica Rejuvenize Peel™ will launch in October 2009 and will be available nationwide at doctor’s offices and medically supervised spas. Visit www.skinmedica.com for locations.

SkinMedica, Inc. is an aesthetic and pharmaceutical company focused on developing, acquiring and commercializing products that improve the appearance of skin and treat dermatologic conditions and diseases.

CONTACT INFORMATION:
Josie Norine
SkinMedica, Inc.
(760) 448-3652
jnorine@skinmedica.com
www.skinmedica.com

###

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream, 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. SkinMedica is based in Carlsbad, California.

TNS Recovery Complex®, VANIQA®, EpiQuin® Micro, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.